Evaluation of drug toxicity in clinical trials

[1]  P. Rutgeerts,et al.  Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. , 2005, The New England journal of medicine.

[2]  Susan Okie,et al.  Raising the safety bar--the FDA's coxib meeting. , 2005, The New England journal of medicine.

[3]  R. Eisenberg.  Learning the value of drugs--is rofecoxib a regulatory success story? , 2005, The New England journal of medicine.

[4]  Susan Okie,et al.  Safety in numbers--monitoring risk in approved drugs. , 2005, The New England journal of medicine.

[5]  J. Spławiński,et al.  Clinical trials: active control vs placebo — What is ethical? , 2004, Science and engineering ethics.

[6]  T. Weihrauch.  Placebo treatment is effective differently in different diseases — but is it also harmless? A brief synopsis , 2004, Science and engineering ethics.

[7]  H. Walach.  Placebo and placebo effects – a concise review , 2003, Focus on Alternative and Complementary Therapies.

[8]  H. Chern,et al.  Placebo Controlled Clinical Trials are as Ethical as Active Controlled Trials Even if Effective Therapies Exist , 2002 .

[9]  A. Koch,et al.  The Impact of Sloppy Study Conduct on Noninferiority Studies , 2002 .

[10]  A. Leuchter,et al.  Changes in brain function of depressed subjects during treatment with placebo. , 2002, The American journal of psychiatry.

[11]  A. Hrõbjartsson,et al.  Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. , 2001, The New England journal of medicine.

[12]  R Day,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[13]  S S Ellenberg,et al.  Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 1: Ethical and Scientific Issues , 2000, Annals of Internal Medicine.

[14]  S. Ellenberg,et al.  Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 2: Practical Issues and Specific Cases , 2000, Annals of Internal Medicine.

[15]  T. Gauler,et al.  Placebo - Efficacy and Adverse Effects in Controlled Clinical Trials , 1999, Arzneimittelforschung.

[16]  T. Kaptchuk,et al.  Powerful placebo: the dark side of the randomised controlled trial , 1998, The Lancet.

[17]  L. Sher.  The placebo effect on mood and behavior: the role of the endogenous opioid system. , 1997, Medical hypotheses.